VIVEbiotech Completes a Key PPQ Campaign for an Ultra Rare Disease Therapy

This week marks an important milestone at VIVEbiotech. Our team successfully completed a PPQ campaign for one of our clients, a step that reinforces our ability to operate at commercial scale.

This specific PPQ is particularly significant, as it supports a lentiviral therapy developed for an ultra‑rare disease. Through this campaign, we help ensure treatment availability for patients in the United States and, ultimately, in the European Union. While the customer remains confidential, the impact on future patients is real and meaningful: bringing high‑quality, complex therapies closer to those with limited options today.

As highlighted by Diego Bochoeyer, Chief Operating Officer at VIVEbiotech, this achievement reflects the commitment, technical excellence, and teamwork of the entire company. Reaching such a milestone is only possible thanks to the dedication and coordinated effort of multiple teams working with purpose and precision.

Looking ahead, we continue with the same energy and sense of responsibility that have guided us from the beginning. High‑quality lentiviral vectors are essential for advancing cell and gene therapies, and we are proud to contribute to that progress every day.

For those seeking a trusted partner in lentiviral vector manufacturing and PPQ support, VIVEbiotech remains committed to delivering excellence across all stages of production.